Oncocyte appoints James Liu as Controller & Principal Accounting Officer

Insight Molecular Diagnostics Inc.

James Liu, 27, appointed Controller & Principal Accounting Officer effective Sept 20, 2022.
Liu previously served as Interim Controller since July 2022 and as Manager of SEC Reporting & Compliance.
Annual salary of $175,000; eligible for discretionary annual bonus with target of 30% of base salary.
Receives one-time grant of 75,000 stock options vesting 25% after 1 year, then monthly over 3 years.
No family relationships or related party transactions with the company's directors or officers.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Liu

Controller & Principal Accounting Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-09-20
Filed: September 26, 2022, 7:59 PM ET

Effective September 20, 2022, Oncocyte Corporation (“Oncocyte” or the “Company”) appointed James Liu as the Company’s Controller & Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Liu was appointed as Controller & Principal Accounting Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Controller & Principal Accounting Officer

Exact text from the filing

Effective September 20, 2022, Oncocyte Corporation (“Oncocyte” or the “Company”) appointed James Liu as the Company’s Controller & Principal Accounting Officer.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-026802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.